SPDYA

Summary

SPDYA (speedy/RINGO cell cycle regulator family member A, HGNC:30613) is a protein-coding gene on chromosome 2p23.2, encoding Speedy protein A (Q5MJ70). Regulates the G1/S phase transition of the cell cycle by binding and activating CDK1 and CDK2.

Enables protein kinase activator activity and protein kinase binding activity. Involved in several processes, including G1/S transition of mitotic cell cycle; positive regulation of cell population proliferation; and positive regulation of protein kinase activity. Located in nucleoplasm.

Source: NCBI Gene 245711 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 36 total
• MANE Select transcript: NM_182756

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30613
Approved symbol	SPDYA
Name	speedy/RINGO cell cycle regulator family member A
Location	2p23.2
Locus type	gene with protein product
Status	Approved
Aliases	SPY1, Ringo3
Ensembl gene	ENSG00000163806
Ensembl biotype	protein_coding
OMIM	614029
Entrez	245711

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 4 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000334056, ENST00000379579, ENST00000439646, ENST00000449210, ENST00000462832, ENST00000467226, ENST00000491044

RefSeq mRNA: 3 — MANE Select: NM_182756 NM_001008779, NM_001142634, NM_182756

CCDS: CCDS1767

Canonical transcript exons

ENST00000334056 — 8 exons

Exon	Start	End
ENSE00001341738	28814613	28814686
ENSE00001859779	28810834	28810947
ENSE00003474611	28819048	28819106
ENSE00003513741	28829148	28829319
ENSE00003555071	28815997	28816249
ENSE00003586086	28822325	28822410
ENSE00003627724	28840172	28840469
ENSE00003847113	28849850	28850610

Expression profiles

Bgee: expression breadth ubiquitous, 163 present calls, max score 91.99.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 45.8500 / max 1113.5447, expressed in 1796 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
19485	45.8500	1796
19499	0.3656	63
19488	0.0603	11
19498	0.0173	4
202136	0.0074	3
202135	0.0071	4

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	91.99	gold quality
right testis	UBERON:0004534	91.93	gold quality
testis	UBERON:0000473	89.32	gold quality
sperm	CL:0000019	87.75	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.12	gold quality
calcaneal tendon	UBERON:0003701	77.44	gold quality
adult organism	UBERON:0007023	77.31	gold quality
lower esophagus mucosa	UBERON:0035834	76.91	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	72.46	gold quality
left ovary	UBERON:0002119	69.89	gold quality
granulocyte	CL:0000094	69.78	gold quality
right ovary	UBERON:0002118	69.60	gold quality
mucosa of transverse colon	UBERON:0004991	69.59	gold quality
cerebellar hemisphere	UBERON:0002245	68.97	gold quality
cerebellar cortex	UBERON:0002129	68.87	gold quality
monocyte	CL:0000576	68.78	gold quality
descending thoracic aorta	UBERON:0002345	68.69	gold quality
endocervix	UBERON:0000458	68.30	gold quality
leukocyte	CL:0000738	68.25	gold quality
ascending aorta	UBERON:0001496	68.19	gold quality
thoracic aorta	UBERON:0001515	67.95	gold quality
body of uterus	UBERON:0009853	67.68	gold quality
right hemisphere of cerebellum	UBERON:0014890	67.56	gold quality
aorta	UBERON:0000947	67.22	gold quality
adrenal tissue	UBERON:0018303	67.19	gold quality
right lobe of liver	UBERON:0001114	66.97	gold quality
popliteal artery	UBERON:0002250	66.94	gold quality
tibial artery	UBERON:0007610	66.93	gold quality
cerebellum	UBERON:0002037	66.79	gold quality
tibial nerve	UBERON:0001323	66.47	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-6379	no	106.28
E-ANND-3	no	2.78

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

37 targeting SPDYA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4645-3P	99.76	69.33	993
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-5580-3P	99.70	69.41	2052
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-578	99.46	68.36	1787
HSA-MIR-21-5P	99.46	70.54	1035
HSA-MIR-208A-5P	99.42	70.83	1913
HSA-MIR-208B-5P	99.42	70.83	1952
HSA-MIR-942-5P	99.41	68.40	1977
HSA-MIR-508-5P	99.41	64.25	1248
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-410-3P	99.27	69.98	2457
HSA-MIR-590-5P	99.25	70.76	930
HSA-MIR-6830-5P	99.01	68.73	1884
HSA-MIR-487A-5P	98.85	69.37	993
HSA-MIR-487B-5P	98.85	69.48	987
HSA-MIR-4635	98.74	67.63	1339
HSA-MIR-2115-5P	98.66	68.07	1191

Literature-anchored findings (GeneRIF, showing 19)

• This protein mediates protection of mammalian cells against DNA damage. (PMID:12839962)
• This study reports that Spy1 expression allows cells to evade checkpoints and apoptosis and suggest that Spy1 regulation of CDK2 is important for the response to DNA damage. (PMID:16951407)
• Spy1 expression enhances CDK2-dependent p27 degradation during late G1 and throughout S-phase (PMID:17671428)
• Spy1 fulfills a novel regulatory role in the intrinsic DNA damage response and maintains the balance between checkpoint activation, apoptosis, repair and cell cycle progression in response to exogenous or intrinsic damage. (PMID:19106603)
• Data show that tight regulation of RINGO/Speedy A is important for the somatic cell cycle. (PMID:19622356)
• Spy1 overexpression is involved in the pathogenesis of hepatocellular carcinoma, it may be a favorable independent poor prognostic parameter for hepatocellular carcinoma. (PMID:19686732)
• Spy1 expression positively correlates with the malignancy of gliomas. (PMID:22447439)
• Our results suggest that Spy1 may be a possible prognostic indicator in NHLs, and it was correlated with phosphorylation of p27(Kip1) on Thr187 (PMID:22492278)
• Cell adhesion to fibronectin down-regulates the expression of Spy1 and contributes to drug resistance in multiple myeloma cells. (PMID:24037419)
• we demonstrate that the atypical cyclin-like protein Spy1 plays a role in balancing the division properties of glioma cells with stemness properties (PMID:24434210)
• CRMP1 interacted with Spy1 which would disturb the association of CRMP1 with actin and was involved in the collapse of growth cones induced by Sema3A and regeneration after sciatic nerve crush. (PMID:25526860)
• A novel Spy1-CLIPR-59 interplay was identified in glioblastoma resistance to TNF-alpha. (PMID:26017671)
• Spy1 participates in the proliferation and apoptosis of epithelial ovarian cancer. (PMID:26644004)
• Authors demonstrate that mammalian Spy1-mediated ERK activation increases ligand-independent phosphorylation and activation of estrogen receptor alpha, correlating with a decrease in tamoxifen sensitivity. (PMID:28423577)
• The authors find that Spy1 confers structural changes to Cdk2 that obviate the requirement of Cdk activation loop phosphorylation. (PMID:28666995)
• This mouse model demonstrates for the first time that degradation of the cyclin-like protein Spy1 is an essential component of p53-mediated tumour suppression. Targeting cyclin-like protein activity may therefore represent a mechanism of re-sensitizing cells to important cell cycle checkpoints in a therapeutic setting. (PMID:31829284)
• Speedy/RINGO protein interacts with ERK/MAPK and PI3K/AKT pathways in SH-SY5Y neuroblastoma cells. (PMID:32602013)
• Salicylidene acylhydrazides attenuate survival of SH-SY5Y neuroblastoma cells through affecting mitotic regulator Speedy/RINGO and ERK/MAPK-PI3K/AKT signaling. (PMID:32691165)
• The SUN1-SPDYA interaction plays an essential role in meiosis prophase I. (PMID:34039995)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	spdya	ENSDARG00000059131
mus_musculus	Spdya	ENSMUSG00000052525
rattus_norvegicus	Spdya	ENSRNOG00000004534

Paralogs (1): SPDYC (ENSG00000204710)

Protein

Protein identifiers

Speedy protein A — Q5MJ70 (reviewed: Q5MJ70)

Alternative names: Rapid inducer of G2/M progression in oocytes A, Speedy-1

All UniProt accessions (4): A0A384MTT5, E7EPV1, Q5MJ70, H7C0J1

UniProt curated annotations — full annotation on UniProt →

Function. Regulates the G1/S phase transition of the cell cycle by binding and activating CDK1 and CDK2. Contributes to CDK2 activation without promoting CDK2 phosphorylation, by inducing a conformation change of the CDK2 T-loop that obstructs the substrate-binding cleft prior to kinase activation. Mediates cell survival during the DNA damage process through activation of CDK2.

Subunit / interactions. Interacts with CDK1. Interacts with CDK2. May interact with CDKN1B/KIP1. Identified in a complex with CDK2 and CDKN1B/KIP1, where it interacts primarily with CDK2.

Subcellular location. Nucleus.

Tissue specificity. Highly expressed in testis. Expressed at a low level in wide range of tissues including bone marrow, brain, heart, kidney, colon, liver, placenta, spleen, skeletal muscle, salivary gland, thyroid gland, thymus, trachea and uterus. Expressed at a slightly higher level in adrenal gland, cerebellum, small intestine, lung, prostate and trachea. Expression is cell cycle-dependent, being restricted to cells in G1/S phase.

Domain organisation. The C-terminus is required for CDK2-activation, but not CDK2-binding.

Similarity. Belongs to the Speedy/Ringo family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q5MJ70-2	2, A2	yes
Q5MJ70-1	1, A1

RefSeq proteins (3): NP_001008779, NP_001136106, NP_877433* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR020984	Speedy	Family
IPR052316	Speedy-Ringo_regulator	Family

Pfam: PF11357

UniProt features (26 total): helix 13, strand 3, region of interest 2, modified residue 2, splice variant 2, mutagenesis site 2, chain 1, turn 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
5UQ2	X-RAY DIFFRACTION	2.7
7E34	X-RAY DIFFRACTION	3.19
5UQ1	X-RAY DIFFRACTION	3.2
5UQ3	X-RAY DIFFRACTION	3.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5MJ70-F1	69.25	0.42

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 222, 224

Mutagenesis-validated functional residues (2):

Position	Phenotype
97	loss of cdk2 activation; when associated with q-135.
135	loss of cdk2 activation; when associated with n-97.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 100 (showing top): GOBP_MEIOTIC_CHROMOSOME_SEGREGATION, GOBP_CHROMOSOME_ORGANIZATION, GOBP_TELOMERE_CAPPING, GOBP_CHROMOSOME_LOCALIZATION, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_CHROMOSOME, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_OOGENESIS, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP, GOBP_TELOMERE_ORGANIZATION, GOBP_MALE_GAMETE_GENERATION, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ORGANELLE, GOMF_KINASE_ACTIVATOR_ACTIVITY, GOBP_ORGANELLE_FISSION, GOBP_CELL_CYCLE_G1_S_PHASE_TRANSITION, GOBP_DNA_DAMAGE_RESPONSE

GO Biological Process (11): G1/S transition of mitotic cell cycle (GO:0000082), DNA damage response (GO:0006974), male meiotic nuclear division (GO:0007140), spermatogenesis (GO:0007283), positive regulation of cell population proliferation (GO:0008284), telomere capping (GO:0016233), oogenesis (GO:0048477), meiotic attachment of telomere to nuclear envelope (GO:0070197), establishment of protein localization to telomere (GO:0070200), positive regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0045737), positive regulation of protein kinase activity (GO:0045860)

GO Molecular Function (3): protein kinase binding (GO:0019901), protein kinase activator activity (GO:0030295), protein binding (GO:0005515)

GO Cellular Component (5): chromosome, telomeric region (GO:0000781), XY body (GO:0001741), nucleus (GO:0005634), nuclear envelope (GO:0005635), nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
male gamete generation	2
protein kinase activity	2
mitotic cell cycle	1
mitotic cell cycle phase transition	1
cell cycle G1/S phase transition	1
cellular response to stress	1
meiotic cell cycle	1
meiotic nuclear division	1
developmental process involved in reproduction	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
telomere maintenance	1
germ cell development	1
female gamete generation	1
meiotic telomere tethering at nuclear periphery	1
chromosome attachment to the nuclear envelope	1
meiotic cell cycle process	1
establishment of protein localization to chromosome	1
regulation of cyclin-dependent protein serine/threonine kinase activity	1
cyclin-dependent protein serine/threonine kinase activity	1
positive regulation of cell cycle	1
positive regulation of protein serine/threonine kinase activity	1
positive regulation of cyclin-dependent protein kinase activity	1
positive regulation of protein phosphorylation	1
positive regulation of kinase activity	1
regulation of protein kinase activity	1
kinase binding	1
kinase activator activity	1
protein kinase regulator activity	1
binding	1
chromosomal region	1
sex chromosome	1
condensed chromatin of inactivated sex chromosome	1
intracellular membrane-bounded organelle	1
nucleus	1
endomembrane system	1
organelle envelope	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

518 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SPDYA	TERB2	Q8NHR7	750
SPDYA	TERB1	Q8NA31	728
SPDYA	CDK2	P24941	636
SPDYA	SUN1	O94901	601
SPDYA	CDKN1B	P46527	591
SPDYA	H0YEC1	H0YEC1	510
SPDYA	CDK1	P06493	509
SPDYA	KHDRBS3	O75525	454
SPDYA	TERF1	P54274	436
SPDYA	ERBB2	P04626	393
SPDYA	KASH5	Q8N6L0	378
SPDYA	NUTM2D	Q5VT03	321
SPDYA	MEIOB	Q8N635	311
SPDYA	SYCP1	Q15431	295
SPDYA	NUP210L	Q5VU65	294

IntAct

14 interactions, top by confidence:

A	B	Type	Score
AQP1	SPDYA	psi-mi:“MI:0915”(physical association)	0.560
CDKN1B	SPDYA	psi-mi:“MI:0915”(physical association)	0.560
CDK5	SPDYA	psi-mi:“MI:0915”(physical association)	0.560
CDK16	SPDYA	psi-mi:“MI:0915”(physical association)	0.370
UBC	SPDYA	psi-mi:“MI:0914”(association)	0.350
SPDYA	SKP2	psi-mi:“MI:0914”(association)	0.350
SKP2	SPDYA	psi-mi:“MI:0914”(association)	0.350
AQP1	SPDYA	psi-mi:“MI:0915”(physical association)	0.000
CDKN1B	SPDYA	psi-mi:“MI:0915”(physical association)	0.000
CDK5	SPDYA	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (35): SPDYA (Affinity Capture-Western), CLIP3 (Affinity Capture-Western), SPDYA (Affinity Capture-RNA), SPDYA (Biochemical Activity), Cdkn1b (Two-hybrid), Cdkn1b (Affinity Capture-Western), CDKN1B (Reconstituted Complex), SPDYA (Reconstituted Complex), SPDYA (Affinity Capture-Western), SPDYA (Affinity Capture-Western), SPDYA (Two-hybrid), CDK5 (Two-hybrid), AQP1 (Two-hybrid), SPDYA (Affinity Capture-RNA), CDK1 (Affinity Capture-Western)

ESM2 similar proteins: A0A494C086, A0A494C0Z2, A0A494C191, A0JPH4, A6NHP3, A6NIY4, A6NJR5, A6NLX3, A6NNV3, A6QLI5, B0BNE4, O08918, O60543, O70302, O75916, P0CI01, P0DTA3, P0DUD1, P0DUD2, P0DUD3, P0DUD4, P0DUX0, P0DUX1, P0DV79, P24864, P39949, P49805, Q12967, Q495Y7, Q495Y8, Q4VXA5, Q4ZIN3, Q5IBH6, Q5IBH7, Q5MJ70, Q5SYB0, Q5XIQ2, Q5ZJR9, Q61457, Q6AYG1

Diamond homologs: A0A494C086, A0A494C0Z2, A0A494C191, A6NHP3, A6NIY4, A6NJR5, A6NKU9, A6NLX3, A6NNV3, P0CI01, P0DTA3, P0DUD1, P0DUD2, P0DUD3, P0DUD4, P0DUX0, P0DUX1, P0DV79, Q495Y7, Q495Y8, Q5IBH6, Q5IBH7, Q5MJ68, Q5MJ70, Q8NFV5, Q8R496, Q9PU13, Q9YGL1

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
SUN1	“up-regulates activity”	SPDYA	binding
SPDYA	“up-regulates activity”	CDK2	relocalization

Disease & clinical

Clinical variants and AI predictions

ClinVar

36 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	28
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1951 predictions. Top by Δscore:

Variant	Effect	Δscore
2:28783899:A:AG	acceptor_gain	1.0000
2:28783900:T:G	acceptor_gain	1.0000
2:28783902:TATA:T	acceptor_loss	1.0000
2:28783903:ATAG:A	acceptor_gain	1.0000
2:28783904:TA:T	acceptor_loss	1.0000
2:28783905:A:AG	acceptor_gain	1.0000
2:28783905:AG:A	acceptor_gain	1.0000
2:28783905:AGG:A	acceptor_loss	1.0000
2:28783906:G:GT	acceptor_gain	1.0000
2:28783906:GG:G	acceptor_gain	1.0000
2:28783906:GGA:G	acceptor_gain	1.0000
2:28783906:GGAT:G	acceptor_gain	1.0000
2:28783906:GGATT:G	acceptor_gain	1.0000
2:28783974:TACAG:T	donor_gain	1.0000
2:28783975:ACAG:A	donor_gain	1.0000
2:28783975:ACAGG:A	donor_loss	1.0000
2:28783976:CAG:C	donor_gain	1.0000
2:28783976:CAGGT:C	donor_loss	1.0000
2:28783977:AG:A	donor_gain	1.0000
2:28783977:AGG:A	donor_loss	1.0000
2:28783978:GG:G	donor_gain	1.0000
2:28783979:G:GA	donor_loss	1.0000
2:28783979:G:GG	donor_gain	1.0000
2:28788653:TAAA:T	acceptor_loss	1.0000
2:28788656:A:AC	acceptor_loss	1.0000
2:28788755:AGTC:A	donor_gain	1.0000
2:28793857:TGACA:T	acceptor_loss	1.0000
2:28793858:GACA:G	acceptor_loss	1.0000
2:28793859:ACAGG:A	acceptor_loss	1.0000
2:28793860:CA:C	acceptor_loss	1.0000

AlphaMissense

2079 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:28840202:T:A	W195R	1.000
2:28840202:T:C	W195R	1.000
2:28829153:T:C	L129P	0.999
2:28829156:C:A	A130D	0.999
2:28829206:T:A	W147R	0.999
2:28829206:T:C	W147R	0.999
2:28829208:G:C	W147C	0.999
2:28829208:G:T	W147C	0.999
2:28829267:T:C	L167P	0.999
2:28840204:G:C	W195C	0.999
2:28840204:G:T	W195C	0.999
2:28840210:A:C	R197S	0.999
2:28840210:A:T	R197S	0.999
2:28819080:G:C	D90H	0.998
2:28819102:A:T	D97V	0.998
2:28822335:C:A	A102D	0.998
2:28822360:G:C	R110S	0.998
2:28822360:G:T	R110S	0.998
2:28822407:C:A	A126D	0.998
2:28822410:T:C	L127P	0.998
2:28829201:T:C	F145S	0.998
2:28829224:T:A	W153R	0.998
2:28829224:T:C	W153R	0.998
2:28829246:T:C	F160S	0.998
2:28829259:G:C	R164S	0.998
2:28829259:G:T	R164S	0.998
2:28829269:T:A	W168R	0.998
2:28829269:T:C	W168R	0.998
2:28840209:G:C	R197T	0.998
2:28840214:C:A	R199S	0.998

dbSNP variants (sampled 300 via entrez): RS1000034166 (2:28822255 A>G), RS1000096406 (2:28826071 G>A), RS1000121486 (2:28830039 T>C), RS1000239799 (2:28810701 G>C,T), RS1000311080 (2:28846203 G>A), RS1000328592 (2:28811587 C>A,T), RS1000416587 (2:28838782 G>A), RS1000547338 (2:28832314 C>A,T), RS1000572239 (2:28810937 G>A,C), RS1000637300 (2:28817078 A>C), RS1000789600 (2:28846340 G>A), RS1000861126 (2:28816672 C>G), RS1000872430 (2:28817090 A>G), RS1000985909 (2:28824483 A>C), RS1001120958 (2:28824765 G>A)

Disease associations

OMIM: gene MIM:614029 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST007656_7	Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)	9.000000e-12

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs12474420	SPDYA		0.00	0

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cadmium Chloride	decreases expression, increases abundance	2
aristolochic acid I	increases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
aflatoxin B2	increases methylation	1
di-n-butylphosphoric acid	affects expression	1
2-palmitoylglycerol	increases expression	1
licochalcone B	increases expression	1
jinfukang	decreases expression	1
theaflavin-3,3’-digallate	affects expression	1
Benzo(a)pyrene	affects methylation	1
Cadmium	decreases expression, increases abundance	1
Cisplatin	decreases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Diethylhexyl Phthalate	increases expression	1
Malathion	increases expression	1
Phthalic Acids	increases methylation	1
Smoke	decreases expression	1
Dihydrotestosterone	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Acrylamide	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.